Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine in Postpartum Depression
NCT00681668Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quetiapine (extended-release tablet, brand name: Bipresso) in postpartum depression (PPD), sponsored by AstraZeneca. Primary endpoint: Hamilton Rating Scale for Depression at 28 weeks. Started Aug 2007; status: terminated.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT00681668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681668.